Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis

Amelia Bercusson, Thomas Colley, Anand Shah, Adilia Warris, Darius Armstrong-James

Research output: Contribution to journalArticle

31 Citations (Scopus)
1 Downloads (Pure)

Abstract

Ibrutinib is a small molecule Bruton tyrosine kinase (Btk) inhibitor approved by the Food and Drug Administration for clinical use in the treatment of chronic lymphocytic leukemia, Waldenström macroglobulinemia, and as a second-line treatment of lymphoma and chronic graft-versus-host disease.1 An association with pulmonary aspergillosis was observed shortly after Ibrutinib was licensed for use.2 A recent phase Ib study of Ibrutinib treatment of primary central nervous system lymphoma reported a 39% incidence of invasive aspergillosis, in patients concurrently treated with corticosteroids, in the absence of neutropenia.3 Studies of Aspergillus fumigatus infection in Btk−/− mice revealed focal pneumonia and large airway mucous plugs, mirroring findings in macrophage-depleted models of pulmonary aspergillosis.
Original languageEnglish
Pages (from-to)1985-1988
Number of pages4
JournalBlood
Volume132
Issue number18
Early online date18 Jul 2018
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint Dive into the research topics of 'Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis'. Together they form a unique fingerprint.

  • Cite this